Medicenna doses first patient in Phase 2 dose expansion of Phase 1/2 ABILITY

Medicenna Therapeutics announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY study evaluating MDNA11, a long-acting, beta-only interleukin-2 super-agonist. “We are excited to dose our first patient in Phase 2 clinical trial as we build critical momentum for MDNA11, a potentially best-in-class, next-generation IL-2 super-agonist for the treatment of advanced solid tumors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “Dosing the first patient in the Phase 2 monotherapy dose expansion portion of the ABILITY study is an important milestone that follows encouraging therapeutic activity and tolerability observed during the Phase 1 dose escalation study. Having established the optimal dosing regimen, we look forward to reporting initial results from the monotherapy and combination arms of the Phase 2 dose expansion portion of the study in the first half of 2024. The combination arm of the trial evaluating MDNA11 with pembrolizumab is expected to commence by the end of this year.” In the Phase 1 monotherapy dose escalation portion of the study, which evaluated 20 patients, MDNA11 was well tolerated with promising single-agent activity. As of the data cutoff date of June 20, 2023, responses included one confirmed durable partial response in a heavily pretreated patient with metastatic pancreatic cancer who continues on treatment with MDNA11 and six patients with stable disease. Of note, one patient with melanoma experienced prolonged stable disease, which lasted over 1.5 years.